Calcitonin Therapy in Osteoporosis

Treatments in Endocrinology

Volumn 3, Issue 2, 2004, Pages 117-132

  Muñoz Torres, Manuel ^a   Alonso, Guillermo ^a   Mezquita Raya, Pedro ^a  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CALCITONIN; CALCITONIN RECEPTOR; CALCIUM; CORTICOSTEROID; PARATHYROID HORMONE[1-34]; RALOXIFENE; SALCATONIN; VITAMIN D;

ABDOMINAL PAIN; ALLOSTERISM; ANALGESIC ACTIVITY; ANOREXIA; APPETITE DISORDER; BONE DENSITY; BONE PAIN; BONE STRENGTH; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CRUSH TRAUMA; DIARRHEA; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG NOMENCLATURE; DRUG TOLERABILITY; EPIGASTRIC DISCOMFORT; FEMALE; FRACTURE; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERSENSITIVITY REACTION; INCIDENCE; LONG TERM CARE; LUMBAR SPINE; MALE; METABOLIC BONE DISEASE; NAUSEA; OSTEOPOROSIS; POOR APPETITE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RHINITIS; RISK FACTOR; SYNDROME; VERTEBRAL CRUSH FRACTURE SYNDROME; VOMITING;

ADMINISTRATION, INTRANASAL; ADRENAL CORTEX HORMONES; ANALGESIA; BONE AND BONES; BONE DENSITY; CALCITONIN; DRUG RESISTANCE; FEMALE; FRACTURES, BONE; HUMANS; MALE; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, CALCITONIN;

EID: 1542619802     PISSN: 11756349     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024677-200403020-00006     Document Type: Review

References (181)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285: 785-95
2. Ray NF, Chan JK, Thamer M. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from The National Osteoporosis Fundation. J Bone Miner Res 1997; 12: 24-35
3. Melton III LJ, Alkinson EJ, Cooper C. Vertebral fractures predict subsequent fractures. Osteoporos Int 1999; 10: 214-21
4. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285: 320-3
5. Curry JD. Power law models for the mechanical properties of cancellous bone. Eng Med 1986; 15: 153-4
6. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related tc, changes in bone density. J Clin Endocrinol Metab 2000; 85: 231-6
7. Hochberg MC, Greenspan S, Wasnich RD, et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002 Apr; 87 (4): 1586-92
8. Faulkner KG. Bone matters: are density increases necessary to reduce fracture risk? J Bone Miner Res 2000; 15: 183-7
9. Delmas PD. How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis? Bone 2000; 27: 1-3
10. Raisz LG, Au WY, Friedman J, et al. Thyrocalcitonin and bone resorption: studies employing a tissue culture bioassay. Am J Med 1967 Nov; 43 (5): 684-90
11. Friedman J, Raisz LG. Thyrocalcitonin, inhibitor of bone resorption in tissue culture. Science 1967; 150: 1465-7
12. Chambers TJ, Magnus CJ. Calcitonin alters behaviour of isolated osteoclasts. J Pathol 1982 Jan; 136 (1): 27-39
13. Body JJ. Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis. Bone 2002 May; 30 (5 Suppl.): 75S-9S
14. Muñoz Torres M, Mezquita Raya P. La calcitonina. Drugs Today (Barc) 1999; 35 (s1): 1-12
15. Plosker GL, McTavish D. Intranasal salcatonin (salmon calcitonin): a review of its pharmacological properties and role in the management of postmenopausal osteoporosis. Drugs Aging 1996 May; 8 (5): 378-400
16. Messer HH, Copp DH. Changes in response to calcitonin following prolonged administration to intact rats. Proc Soc Exp Biol Med 1974; 146: 643-7
17. Goldring SR, Gorn AH, Yamin M, et al. Characterization of the structural and functional properties of cloned calcitonin receptor cDNAs. Horm Metab Res 1993; 25: 477-80
18. Zaidi M, Shankar VS, Huang CL-H, et al. Molecular mechanisms of calcitonin action. Endocr J 1994; 2: 459-67
19. Alam ASMT, Bax CMR, Shankar VS, et al. Further studies on the mode of action of calcitonin on isolated rat osteoclasts: pharmacological evidence for a second size mediating intracellular Ca2+ mobilization and cell retraction. J Endocrinol 1993; 136: 7-15
20. Yamin M, Gorn AH, Flannery MR, et al. Cloning and characterization of a mouse brain calcitonin receptor complementary deoxyribonucleic acid and mapping of the calcitonin receptor gene. Endocrinology 1997; 135: 2635-43
21. Inoue D, Shih C, Galson DL, et al. Calcitonin-dependent down-regulation of the mouse C1a calcitonin receptor in cells of the osteoclast lineage involves a transcriptional mechanism. Endocrinology 1999; 140: 1060-8
22. Wada S, Akatsu T, Tamura T, et al. Glucocorticoid regulation of calcitonin receptor in mouse osteoclast-like multinucleated cells. J Bone Miner Res 1994; 9: 1705-12
23. Takahashi S, Goldring SR, Katz M, et al. Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation. J Clin Invest 1995; 95: 167-71
24. Tverberg LA, Gustafson MF, Scott TL, et al. Induction of calcitonin and calcitonin receptor expression in rat mammary tissue during pregnancy. Endocrinology 2000; 141: 3696-702
25. Jagger C, Chambers TJ, Pondel M. Transgenic mice reveal novel sites of calcitonin receptor gene expression during development. Biochem Biophys Res Commun 2000; 274: 124-9
26. Kappas S, Clark AJL. Identification of an orphaned receptor gene as a type 1 calcitonin gene-related peptide receptor. Biochem Biophys Res Commun 1995; 217: 832-8
27. Aiyar N, Rand K, Elshourbagy NA, et al. A cDNA encoding the calcitonin gene-related peptide type-1 receptor. J Biol Chem 1996; 271: 11325-9
28. Wimalawansa SJ. Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology and therapeutic potential. Endocr Rev 1996; 17: 533-85
29. Stroop SD, Moore EE. Intracellular calcium increases mediated by a recombinant human calcitonin receptor. J Bone Miner Res 1995; 10: 524-32
30. Stroop SD, Moore EE, Kuestner RE, et al. Modulation of calcitonin binding by calcium: differential effects of divalent cations. J Recept Res 1993; 13: 1173-97
31. Stroop SD, Thompson DL, Kuestner RE, et al. A recombinant human calcitonin receptor functions as an extracellular calcium sensor. J Biol Chem 1993; 268: 19927-30
32. Anandathreethavarada HK, Biswas G, Toshiya A, et al. CD38/ADP-ribosyl cyclase: a new role in the regulation of osteoclastic bone resorption. J Cell Biol 1999; 146: 1161-72
33. Zaidi M, Shankar VS, Adebanjo OA, et al. Regulation of extracellular calcium-sensing in rat osteoclasts by femtomolar calcitonin concentrations. Am J Physiol 1996; 271: F637-44
34. Zaidi M, Shankar VS, Tunwell RE, et al. A ryanodine receptor-like molecule in the osteoclast plasma membrane is a functional component of the osteoclast Ca2+ sensor. J Clin Invest 1995; 96: 1582-90
35. Orcell P, Tajima H, Murayama Y, et al. Multiple domains interacting with Gs in the porcine calcitonin receptor. Mol Endocrinol 2000; 14: 170-82
36. Breimer LH, MacIntyre I, Zaidi M. Peptides from the calcitonin genes: molecular genetics, structure and function. Biochem J 1988; 255: 377-90
37. Chambers TJ, Magnus CJ. Calcitonin alters behaviour of isolated osteoclasts. J Pathol 1982; 136: 97-106
38. Holtrop NE, Raisz LJ, Simmons HA. The effects of parathyroid hormone, colchicines and calcitonin on the ultrastructure and the activity of osteoclasts in organ culture. J Cell Biol 1974; 60: 346-55
39. Kallio DM, Ganat PR, Minkin C. Ultrastructural effects of calcitonin on osteoclasts in tissue culture. J Ultrastruct Res 1972; 39: 205-16
40. Chambers TJ. Osteoblasts release osteoclasts from calcitonin-induced quiescence. J Cell Sci 1982; 57: 247-53
41. Zaidi M, Alam ASMT, Shankar VS, et al. A quantitative description of components of in vitro morphometric change in the rat osteoclast model: relationships with cellular function. Eur Biophys J 1992; 21: 349-55
42. Yumita S, Nicholson GC, Rowe DJ, et al. Biphasic effect of calcitonin on tartrate-resistant acid phosphatase activity in isolated rat osteoclasts. J Bone Miner Res 1991; 6: 591-7
43. Akisaka T, Gay CV. Ultracytochemical evidence for a proton pump adenosine trisphosphate in chick osteoclasts. Cell Tissue Res 1986; 245: 507-12
44. Chambers TJ, Fuller K, Darby JA. Hormonal regulation of acid phosphatase release by osteoclasts disaggregated from neonatal rat bone. J Cell Physiol 1987; 132: 90-6
45. Moonga BS, Moss DW, Patchell A, et al. Intracellular regulation of enzyme secretion from rat osteoclasts and evidence for a functional role in bone resorption. J Physiol 1990; 429: 29-45
46. Chambers TJ, McSheehy PMJ, Thompson BM, et al. The effect of calcium regulating hormones and prostaglandins on bone resorption by osteoclasts disaggregated from rabbit long bones. Endocrinology 1985; 116: 234-9
47. Dempster DW, Murills RJ, Horbert W, et al. Biological activity of chicken calcitonin: effects on neonatal rat and embryonic chick osteoclasts. J Bone Miner Res 1987; 2: 443-8
48. Zaidi M, Fuller K, Bevis PJR, et al. Calcitonin gene-related peptide inhibits osteoclastic bone resorption: a comparative study. Calcif Tissue Int 1987; 40: 149-54
49. Okubo Y, Bessho K, Fujimura K, et al. Effect of e-calcitonin on osteoinduction by recombinant human bone morphogenetic protein-2. Biochem Biophys Res Commun 2000; 269: 317-21
50. Wallach S, Rousseau G, Martin L, et al. Effects of calcitonin on animal and in vitro models of skeletal metabolism. Bone 1999; 25: 509-16
51. Farley J, Dimai HP, Stilt-Coffing B, et al. Calcitonin increases the concentration of insulin-like growth factors in serum-free cultures of human osteoblast-like cells. Calcif Tissue Int 2000; 67: 247-54
52. Plotkin LI, Weinstein RS, Parfitt AM, et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999; 104: 1363-74
53. Mancini L, Moradi-Bidhendi N, Brandi ML, et al. Modulation of the effects of osteoprotegrin (OPG) ligand in a human leukemic cell line by OPG and calcitonin. Biochem Biophys Res Commun 2000; 279: 391-7
54. Agus ZS, Wasserstein S, Goldfarb S. PTH, calcitonin, cyclic nucleotides and the kidney. Annu Rev Physiol 1981; 43: 583-95
55. Zaidi M, Brain SD, Tippins JR, et al. Structure-activity relationship of human calcitonin gene-related peptide. Biochem J 1990; 269: 775-80
56. Shinki T, Ueno Y, DeLuca HF, et al. Calcitonin is a major regulator for the expression of renal 25-hydroxyvitaminD3-1-alpha-hydroxylase gene in normocalcemic rats. Proc Natl Acad Sci U S A 1999; 96: 8253-8
57. Yoshida N, Yoshida T, Nakamura A, et al. Calcitonin induces 25-hydroxyvitamin D3 1alpha hydroxylase mRNA expression via protein kinase C pathway in LLCPK1 cells. J Am Soc Nephrol 1999; 10: 2474-9
58. Chakraborty M, Chatterjee D, Gorelick FS, et al. Cell cycle dependent kinase-specific regulation of the apical Na/H exchanger and the Na, K-ATPase in the kidney cell line LLCPK1 by calcitonin. Proc Natl Acad Sci U S A 1994; 91: 2115-9
59. Burckhardt P, Singer FR, Potts Jr JT. Parathyroid function in patients with Paget's disease treated with salmon calcitonin. Clin Endocrinol 1973; 2: 15-22
60. Kraenzlin ME, Seibel MJ, Trechsel U, et al. The effect of intranasal salmon calcitonin on postmenopausal bone turnover as assessed by biochemical markers: evidence of maximal effect after 8 weeks of continuous treatment. Calcif Tissue Int 1996; 58: 216-20
61. Woodhouse NJ, Mohamedally SM, Saed-Nejad F, et al. Development and significance of antibodies to salmon calcitonin in patients with Paget's disease on long-term treatment. BMJ 1977 Oct 8; 2 (6092): 927-9
62. Singer FR, Fredericks RS, Minkin C. Salmon calcitonin therapy for Paget's disease of bone: the problem of acquired clinical resistance. Arthritis Rheum 1980 Oct; 23 (10): 1148-54
63. Levy F, Muff R, Dotti-Sigrist S, et al. Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of Paget's disease. J Clin Endocrinol Metab 1988 Sep; 67 (3): 541-5
64. Grauer A, Frank-Raue K, Schroth J, et al. Neutralizing antibodies against salmon calcitonin: the cause of a treatment failure in Paget's disease [in German]. Dtsch Med Wochenschr 1994 Apr 8; 119 (14): 507-10
65. Chesnut III CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study: PROOF Study Group. Am J Med 2000; 109: 267-76
66. Grauer A, Ziegler R, Raue F. Clinical significance of antibodies against calcitonin. Exp Clin Endocrinol Diabetes 1995; 103 (6): 345-51
67. Grauer A, Reinel HH, Lunghall S, et al. Formation of neutralizing antibodies after treatment with human calcitonin. Am J Med 1993 Oct; 95 (4): 439-42
68. Reginster JY, Gaspar S, Deroisy R, et al. Prevention of osteoporosis with nasal salmon calcitonin: effect of anti-salmon calcitonin antibody formation. Osteoporos Int 1993 Sep; 3 (5): 261-4
69. Reginster JY, Azria M, Gaspar S, et al. Endogenous production of specific antibodies does not decrease hypocalcemic response to calcitonin in young rabbits. Calcif Tissue Int 1992 Jun; 50 (6): 518-20
70. Hosking DJ, Denton LB, Cadge B, et al. Functional significance of antibody formation after long-term salmon calcitonin therapy. Clin Endocrinol (Oxf) 1979 Mar; 10 (3): 243-52
71. Grauer A, Reinel HH, Ziegler R, et al. Neutralizing antibodies against calcitonin. Horm Metab Res 1993 Sep; 25 (9): 486-8
72. Muff R, Dambacher MA, Fischer JA. Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of postmenopausal osteoporosis. Osteoporos Int 1991 Feb; 1 (2): 72-5
73. Wada S, Udagawa N, Nagata N, et al. Calcitonin receptor down-regulation relates to calcitonin resistance in mature mouse osteoclasts. Endocrinology 1996 Mar; 137 (3): 1042-8
74. Wener JA, Gorton SJ, Raisz LG. Escape from inhibition or resorption in cultures of fetal bone treated with calcitonin and parathyroid hormone. Endocrinology 1972; 90 (3): 752-9
75. Wada S, Udagawa N, Akatsu T, et al. Regulation by calcitonin and glucocorticoids of calcitonin receptor gene expression in mouse osteoclasts. Endocrinology 1997; 138: 521-9
76. Rakopoulos M, Ikegame M, Findlay DM, et al. Short treatment of osteoclasts in bone marrow culture with calcitonin causes prolonged suppression of calcitonin receptor mRNA. Bone 1995; 17: 447-53
77. Ikegame M, Rakopoulos M, Martin TJ, et al. Effects of continuous calcitonin treatment on osteoclast-like cell development and calcitonin receptor in mouse bone marrow cultures. J Bone Miner Res 1996; 11: 456-65
78. Overgaard K, Agnusdei D, Hansen MA, et al. Dose-response bioactivity and bioavailability of salmon calcitonin in premenopausal and postmenopausal women. J Clin Endocrinol Metab 1991; 72: 344-9
79. Lee WA, Ennis RD, Longenecker JP, et al. The bioavailability of intranasal salmon calcitonin in healthy volunteers with and without a permeation enhancer. Pharm Res 1994 May; 11 (5): 747-50
80. Plosker GL, McTavish D. Intranasal salcatonin (salmon calcitonin): a review of its pharmacological properties and role in the management of postmenopausal osteoporosis. Drugs Aging 1996 May; 8 (5): 378-400
81. Lee YH, Sinko PJ. Oral delivery of salmon calcitonin. Adv Drug Deliv Rev 2000; 42: 225-38
82. Torres-Lugo M, Peppas NA. Transmucosal delivery systems for calcitonin: a review. Biomaterials 2000; 21: 1191-6
83. Sakuma S, Hayashi M, Akashi M. Design of nanoparticles composed of graft copolymers for oral peptide delivery. Adv Drug Deliv Rev 2001; 47: 21-37
84. Millest AJ, Evans JR, Young JJ, et al. Sustained release of salmon calcitonin in vivo from lactide-glycolide copolymer depots. Calcif Tissue Int 1993; 52: 361-4
85. New R, Littlewood G, Guard P, et al. Intestinal delivery of calcitonin in pig. Int J Pharm 1997; 156: 1-8
86. Dogru ST, Calis S, Öner F. Oral multiple w/o/w emulsion formulation of a peptide salmon calcitonin: in vitro-in vivo evaluation. J Clin Pharm Ther 2000; 25: 435-43
87. Lee YH, Perry BA, Sutyak JP. Regional differences in intestinal spreading and pH recovery and the impact on salmon calcitonin absorption in dogs. Pharmacol Res 2000; 17: 284-90
88. Leone-Bay A, Paton DR, Weidner JJ. The development of delivery agents that facilitate the oral absorption of macromolecular drugs. Med Res Rev 2000; 20: 169-86
89. Buclin T, Cosma Rochat M, Burckhardt P, et al. Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. J Bone Miner Res 2002 Aug; 17 (8): 1478-85
90. Buclin T, Randin JP, Jacquet AF, et al. The effect of rectal and nasal administration of salmon calcitonin in normal subjects. Calcif Tissue Int 1987 Nov; 41 (5): 252-8
91. Overgaard K, Hansen MA, Dirksen KL, et al. Rectal salmon calcitonin for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 1992 Sep; 51 (3): 184-8
92. Kollerup G, Hermann AP, Brixen K, et al. Effects of salmon calcitonin suppositories on bone mass and turnover in established osteoporosis. Calcif Tissue Int 1994 Jan; 54 (1): 12-5
93. Lyritis GP, Ioannidis GV, Karachalios T, et al. Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study. Clin J Pain 1999; 15: 284-9
94. Chang SL, Hoffman G, Deftos LJ, et al. Transdermal iontophoretic delivery of salmon calcitonin. Int J Pharm 2000; 25: 10-3
95. Nakamura K, Katagai K, Mori K, et al. Transdermal administration of salmon calcitonin by pulse depolarization-iontophoresis in rats. Int J Pharm 2001 May 7; 218 (1-2): 93-102
96. Chang SL, Hofmann GA, Zhang L, et al. Stability of a transdermal salmon calcitonin formulation. Drug Deliv 2003; 10 (1): 41-5
97. Deftos LJ, Nolan JJ, Seely BL, et al. Intrapulmonary drug delivery of salmon calcitonin. Calcif Tissue Int 1997 Oct; 61 (4): 345-7
98. Reginster JY, Franchimont P. Side-effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection. Clin Exp Rheumatol 1985; 3: 155-7
99. Hosking DJ. Paget's disease of bone: an update on management. Drugs 1985; 30: 156-73
100. Muñoz Torres M, Quesada Charneco M, Torres Vela E, et al. Valoración de la calcitonina nasal e inyectable en la osteoporosis postmenopáusica. REEMO 1994; 3: 9-11
101. Gennari C, Passeri M, Chierichetti SM, et al. Side-effects of synthetic salmon and human calcitonin. Lancet 1983; 1: 594-5
102. Foti R, Martorana U, Broggini M. Long-term tolerability of nasal spray formulation of salmon calcitonin. Curr Ther Res 1995; 56 Suppl. 4: 429-35
103. Overgaard K, Hansen MA, Jensen SB, et al. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992; 305: 556-61
104. Thamsborg G, Storm TL, Sykulski R, et al. Effect of different doses of nasal salmon calcitonin on bone mass. Calcif Tissue Int 1991; 41: 302-7
105. Regirster JY, Deroisy R, Lecart MP, et al. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. Am J Med 1995; 98: 452-8
106. Rico H, Revilla M, Hernandez ER, et al. Total and regional bonemineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study. Calcif Tissue Int 1995; 56: 181-5
107. Stock JL, Avioli LV, Baylink DJ. Calcitonin-salmon nasal sprayreduces the incidence of new vertebral fractures in postmenopausal women: three-year interim results of the PROOF study [abstract 187]. J Bone Miner Res 1997; 12 Suppl. 1: S149
108. Schelemmer A, Ravn P, Hassager C, et al. Morning or evening administration of nasal calcitonin? Effects on biochemical markers of bone turnover. Bone 1997; 20: 63-7
109. Legrand E, Chappard D, Pascaretti C, et al. Trabecular bone microarchitecture, bone mineral density, and vertebral fractures in male osteoporosis. J Bone Miner Res 2000; 15: 13-9
110. Ettinger B, Black DM, Mirtlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999; 282: 637-45
111. Turner CH. Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int 2002; 13 (2): 97-104
112. Dempster DW. The impact of bone turnover and bone-active agents on bone quality: focus on the hip. Osteoporos Int 2002 May; 13 (5): 349-52
113. Thamsborg G, Jensen J, Kollerup G, et al. Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis. Bone 1996; 19: 207-12
114. Reginster JY, Denis D, Albert A, et al. 1-year controlled randomised trial of pievention of early postmenopausal bone loss by intranasal calcitonin. Lancet 1987; 11: 1481-3
115. Reginster JY, Meurmans L, Deroisy R, et al. A 5-year controlled randomised study of prevention of early postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium. Eur J Clin Invest 1994; 24: 565-9
116. Overgaard K, Riis BJ, Christiansen C, et al. Effect of salcatonin given intranasally on early postmenopausal bone loss. BMJ 1989; 299: 477-9
117. Gennari C, Agnusdei D, Montagnani N, et al. An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss. Calcif Tissue Int 1992; 50: 381-2
118. Arnala I, Saastamoinen J, Alhava EM. Salmon calcitonin in the prevention of bone loss at perimenopause. Bone 1996; 18: 62-632
119. Overgaard K, Hansen MA, Nielsen VH, et al. Discontinuous calcitonin treatment of established osteoporosis: effects of withdrawal of treatment. Am J Med 1990; 89: 1-6
120. Lyritis GP, Magiasis B, Tsakalakos N. Prevention of bone loss in early nonsurgical and nonosteoporotic high turnover patients with salmon calcitonin: the role of biochemical bone markers in monitoring high turnover patients under calcitonin treatment. Calcif Tissue Int 1995; 56: 38-41
121. Overgaard K, Riis BJ, Christiansen C, et al. Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol 1989; 30: 435-42
122. Ellerington M, Hillard TC, Whitcroft SI, et al. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. Calcif Tissue Int 1996; 59: 6-11
123. Rico H, Hernandez ER, Revilla M, et al. Salmon calcitonin reduces vertebral fiacture rate in postmenopausal crush fracture syndrome. Bone Miner 1992 Feb; 16 (2): 131-8
124. Hizmetli S, Elden H, Kaptanoglu E, et al. The effect of different doses of calcitonin on bone mineral density and fracture risk in postmenopausal osteoporosis. Int J Clin Pract 1998 Oct; 52 (7): 453-5
125. Silverman SL, Chesnut C, Baylink D, et al. Salmon calcitonin nasal spray is effective and safe in older osteoporotic women: results from the PROOF Study. J Bone Miner Res 2001; 16 Suppl. 1: S530-M414
126. Dempster DW. The contribution of trabecular architecture to cancellous bone quality. J Bone Miner Res 2000; 15: 20-3
127. Kanis JA, McCloskey EV. Effect of calcitonin on vertebral and other fractures. QJM 1999; 92: 143-9
128. Cranney A, Tugwell P, Zytaruk N, et al. The Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis: VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev 2002 Aug; 23 (4): 540-51
129. Cranney A, Guyatt G, Griffith L, et al. The Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analysis analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002 Aug; 23 (4): 570-8
130. Kanis JA, Johnell O, Gullberg B, et al. Evidence of efficacy of drugs affecting bone metabolism in preventing hip fracture. BMJ 1992; 305: 1124-8
131. Lyritis GP, Trovas G. Analgesic effects of calcitonin. Bone 2002 May; 30 (5 Suppl. 1): 71-4
132. Gennari C. Analgesic effect of calcitonin in osteoporosis. Bone 2002 May; 30 (5 Suppl. 1): 67-70
133. Appelboom T. Calcitonin in reflex sympathetic dystrophy syndrome and other painful conditions. Bone 2002 May; 30 (5 Suppl.): 84S-6S
134. Lyritis GP, Paspati I, Karachalios T, et al. Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures: a double-blind, placebo-controlled clinical study. Acta Orthop Scand Suppl 1997; 275: 112-4
135. Maksymowych WP. Managing acute osteoporotic vertebral fractures with calcitonin. Can Fam Physician 1998 Oct; 44: 2160-6
136. Pontiroli AE, Pajetta E, Scaglia L, et al. Analgesic effect of intranasal and intramuscular salmon calcitonin in post-menopausal osteoporosis: a double-blind, double-placebo study. Aging (Milano) 1994 Dec; 6 (6): 459-63
137. Kapuscinski P, Talalaj M, Borowicz J, et al. An analgesic effect of synthetic human calcitonin in patients with primary osteoporosis. Mater Med Pol 1996 Jul-Sep; 28 (3): 83-6
138. Vescovi PP, Pedrazzoni M, Gerra G, et al. Salmon calcitonin given by nasal spray or by injection does not increase beta-endorphin levels in normal men. Life Sci 1990; 47: 1469-73
139. Braga PC. Calcitonin and its antinociceptive activity: animal and human investigations 1975-1992. Agents Actions 1994; 41: 121-31
140. Franceschini R, Cataldi A, Barreca T, et al. Plasma beta-endorphin, ACTH and cortisol secretion in man after nasal spray administration of calcitonin. Eur J Clin Pharmacol 1989; 37: 341-3
141. Orwoll ES. Osteoporosis in men. Endocrinol Metab Clin North Am 1998 Jun; 27 (2): 349-67
142. Eastell R, Boyle IT, Compston J, et al. Management of male osteoporosis: report of the UK Consensus Group. QJM 1998; 91: 71-92
143. Trovas GP, Lyritis GP. Aetiology in male osteoporosis. J Bone Miner Res 1997; 12: S1, S370
144. Kelepouris N, Harper KD, Gannon F. Severe osteoporosis in men. Ann Intern Med 1998; 123: 452-60
145. Peris P, Guanabens N, Monegal A. Aetiology and presenting symptoms in male osteoporosis. Br J Rheumatol 1995; 34: 936-41
146. Melton III LJ. Epidemiology of fractures. In: Riggs BL, Melton III LJ, editors. Osteoporosis: etiology, diagnosis and management. New York: Raven Press, 1998: 133-54
147. Agrawal R, Wallach S, Cohn S, et al. Calcitonin treatment of osteoporosis. In: Pecile A, editor. Calcitonin. Amsterdam: Excerpta Medica, 1981: 237-46
148. Trovas GP, Lyritis GP, Galanos A, et al. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers. J Bone Miner Res 2002 Mar; 17 (3): 521-7
149. Dequeker J, Westhovens R, Luyten FP. Rheumatic disorders and glucocorticoid-induced osteoporosis. Front Horm Res 2002; 30: 107-20
150. Malerba M, Romanelli G, Grassi V. Glucocorticoid-induced osteoporosis in asthma and respiratory diseases. Front Horm Res 2002; 30: 86-93
151. Manolagas SC. Corticosteroids and fractures: a close encounter of the third cell kind. J Bone Miner Res 2000 Jun; 15 (6): 1001-5
152. Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci 2002 Jun; 966: 73-81
153. Dennison E, Cooper C. Epidemiology of glucocorticoid-induced osteoporosis. Front Horm Res 2002; 30: 121-6
154. Van Staa TP, Leufkens HG, Abenhaim L, et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000 Dec; 39 (12): 1383-9
155. Sambrook PN, Birmingham J, Kelly P, et al. Prevention of corticosteroid osteoporosis: a comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993; 328: 1747-52
156. Healey JH, Paget SA, Williams-Russo P, et al. A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica. Calcif Tissue Int 1996; 58: 73-80
157. Adachi JD, Bensen WG, Bell MJ, et al. Salmon calcitonin nasal spray and the prevention of corticosteroid-induced osteoporosis. Br J Rheumatol 1997; 36: 255-9
158. Luengo M, Pons F, Martinez de Osaba JM, et al. Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study. Thorax 1994; 49: 1099-102
159. Kotaniemi A, Piirainen H, Paimela L, et al. Is continuous intranasal salmon calcitonin effective in treating axial bone loss in patients with active RA receiving low-dose glucocorticoid? J Rheumatol 1996; 23: 1875-9
160. Ringe JD, Welzel D. Salmon calcitonin in the therapy of corticosteroid-induced osteoporosis. Eur J Clin Pharmacol 1987; 33: 35-9
161. Luengo M, Picado C, Del Rio L, et al. Treatment of steroid-induced osteopenia with calcitonin in corticosteroid-dependent asthma. Am Rev Respir Dis 1990; 142: 104-7
162. Cranney A, Welch V, Adachi JD, et al. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000; (2): CD001983
163. Canalis E, Giustina A. Glucocorticoid-induced osteoporosis: summary of a workshop. J Clin Endocrinol Metab 2001 Dec; 86 (12): 5681-5
164. Yeap SS, Hosking DJ. Management of corticosteroid-induced osteoporosis. Rheumatology (Oxford) 2002 Oct; 41 (10): 1088-94
165. Roux C, Dougados M. Calcitonin in glucocorticoid-induced osteoporosis. Front Horm Res 2002; 30: 145-9
166. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001 Jul; 44 (7): 1496-503
167. Leuthauser K, Gujer R, Aldecoa A, et al. Receptor-activity-modifying protein 1 forms heterodimers with two G-protein-coupled receptors to define ligand recognition. Biochem J 2000; 2: 347-51
168. Samura A, Wada S, Suda S, et al. Calcitonin receptor regulation and responsiveness to calcitonin in human osteoclast-like cells prepared in vitro using receptor activator of nuclear factor kappaB ligand and macrophage colony-stimulating factor. Endocrinology 2000; 141: 3774-82
169. Suva LJ, Flannery MS, Caulfield MP, et al. Design, synthesis and utility of novel benzophenone-containing calcitonin analogs for photoaffinity labeling the calcitonin receptor. J Pharmacol Exp Ther 1997; 283: 876-88
170. Armour SL, Foord S, Kenakin T, et al. Pharmacological characterization of receptor-activity-modifying proteins (RAMPs) and the human calcitonin receptor. J Pharmacol Toxicol Methods 1999; 42: 217-24
171. Collins MT, Skarulis MC, Bilezikian JP, et al. Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 1998; 83: 1083-8
172. Goodman WG, Frazao JM, Goodkin DA, et al. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 2000; 58: 436-45
173. Silverberg SJ, Bone HG, Marriott TB, et al. Short term inhibition of parathyroid hormone secretion by a calcium receptor agonist in patients with primary hyperparathyroidism. N Engl J Med 1997; 337: 1506-10
174. Shoback DM, Bilezikian JP, Turner SA, et al. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88 (12): 5644-9
175. Morley P, Whitfield JF, Willick GE. Parathyroid hormone: an anabolic treatment for osteoporosis. Curr Pharm Des 2001; 7: 671-97
176. Neer RM, Arnaud CD, Zanchetta JR. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-41
177. Hodsman AB, Fraher LJ. Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients. Bone Miner 1990 May; 9 (2): 137-52
178. Hodsman AB, Steer BM, Fraher LJ, et al. Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients. Bone Miner 1991 Jul; 14 (1): 67-83
179. Hodsman AB, Fraher LJ, Ostbye T, et al. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J Clin Invest 1993 Mar; 91 (3): 1138-48
180. Hodsman AB, Fraher LJ, Watson PH, et al. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 1997 Feb; 82 (2): 620-8
181. DeLuca PP, Dani BA. Skeletal effects of parathyroid hormone (1-34) in ovariectomized rats with or without concurrent administration of salmon calcitonin. AAPS PharmSci 2001; 3 (4): E27